TNF and inflammatory bowel disease: Immunomodulator co-therapy with both IFX/ADA associated with less treatment failure - unplanned IBD-related hospitalization, IBD-related resective surgery, new/recurrent corticosteroid use or anti-TNF switch [CD: adjusted hazard ratio (aHR) 0.77, 95% CI 0.66–0.90; UC: aHR 0.72, 95% CI 0.62–0.84]. AZA superior to MTX as co-therapy in UC.